Last reviewed · How we verify
Bupivacaine HCl Treatment 2c
Bupivacaine HCl is a local anesthetic that blocks nerve impulses, preventing pain.
Bupivacaine HCl is a local anesthetic that blocks nerve impulses, preventing pain. Used for Local anesthesia for surgical procedures.
At a glance
| Generic name | Bupivacaine HCl Treatment 2c |
|---|---|
| Sponsor | Durect |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the sodium channels in nerve fibers, which prevents the initiation and transmission of nerve impulses, thereby blocking pain signals to the brain.
Approved indications
- Local anesthesia for surgical procedures
Common side effects
- Central nervous system depression
- Cardiovascular effects
- Respiratory depression
Key clinical trials
- An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery (PHASE2)
- An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine HCl Treatment 2c CI brief — competitive landscape report
- Bupivacaine HCl Treatment 2c updates RSS · CI watch RSS
- Durect portfolio CI